AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £574.22m
- £597.07m
- £55.20m
REG - Allergy Therapeutics - Block Listing Interim Review
AnnouncementREG - Allergy Therapeutics - Result of Annual General Meeting
AnnouncementREG - Allergy Therapeutics - Positive Interim Data from PROTECT Trial
AnnouncementREG - Allergy Therapeutics - First Patient Dosed in G308 Paediatric Trial
AnnouncementREG - Allergy Therapeutics - Submission of MAA for Grass MATA MPL
AnnouncementREG - Allergy Therapeutics - Notice of 2024 Annual General Meeting
AnnouncementREG - Allergy Therapeutics - Audited Preliminary Results 2024
AnnouncementREG - ZQ Capital Limited - Rule 19.6(c) Confirmation
AnnouncementREG - Allergy Therapeutics - Commencement of Phase III Paediatric Trial
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - Update on funding and preliminary results
AnnouncementREG - Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - Trading update for the year ended 30 June 2024
AnnouncementREG - Allergy Therapeutics - Appointment of Nominated Adviser and Sole Broker
AnnouncementREG - Allergy Therapeutics - Launch of new Company Long Term Incentive Plan
AnnouncementREG - Allergy Therapeutics - Appointment of Non-Executive Director
AnnouncementREG - Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial
AnnouncementREG - Allergy Therapeutics - Successful meetings with Paul Ehrlich Institut
Announcement